TerminatedPhase 2NCT04469725
KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma
Studying Thymic carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Principal Investigator
- Xiaolong Fu, MDShanghai Chest Hospital
- Intervention
- KN046(drug)
- Enrollment
- 95 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2023
Study locations (1)
- Shanghai Chest Hospital, Shanghai, Shanghai Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04469725 on ClinicalTrials.govOther trials for Thymic carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07132918HEARTS Trial for Thoracic CancersUniversity of Wisconsin, Madison
- RECRUITINGPHASE2NCT06838910Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic CarcinomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGNANCT06692062Hypofractionated Radiotherapy for Thymic Epithelial TumorsRongrong Zhou
- RECRUITINGPHASE2NCT06248515A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial TumorsGeorgetown University
- RECRUITINGPHASE3NCT06402708Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)Fudan University
- RECRUITINGPHASE3NCT02633514Adjuvant Treatment for Incomplete Resection Thymoma or Thymic CarcinomaFudan University
- RECRUITINGPHASE2NCT05832827First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)National Cancer Center, Japan
- RECRUITINGNCT06301945Artificial Intelligence Prediction Tool in Thymic Epithelial TumorsErasmus Medical Center